Adaptimmune Therapeutics plc (NASDAQ:ADAP) Weekly Ratings as of May 17, 2018

May 17, 2018 - By William Cox

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Corporate Logo

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ratings Coverage

In total 3 analysts cover Adaptimmune Therapeutics (NASDAQ:ADAP). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 3 are the (NASDAQ:ADAP)’s analyst reports since March 16, 2018 according to StockzIntelligence Inc. The stock rating was maintained by Cowen & Co with “Buy” on Friday, March 16. In Friday, March 16 report Leerink Swann initiated it with “Buy” rating and $15.0 target. Listed here are Adaptimmune Therapeutics plc (NASDAQ:ADAP) PTs and latest ratings.

16/03/2018 Broker: Cowen & Co Rating: Buy Maintain
16/03/2018 Broker: Raymond James Rating: Buy New Target: $20.0
16/03/2018 Broker: Leerink Swann Rating: Buy New Target: $15.0 Initiate

ADAP is reaching $12.14 during the last trading session, after decreased 1.38%.Currently Adaptimmune Therapeutics plc is uptrending after 144.20% change in last May 17, 2017. ADAP has also 124,066 shares volume. ADAP outperformed by 132.65% the S&P 500.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform.The firm is valued at $1.14 billion. The Company’s platform enables to identify cancer targets; find and genetically engineer T-cell receptors ; and produce TCR therapeutic candidates for administration to patients.Last it reported negative earnings. The companyÂ’s lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma.

For more Adaptimmune Therapeutics plc (NASDAQ:ADAP) news released briefly go to: Nasdaq.com, Benzinga.com, Globenewswire.com, Streetinsider.com or Seekingalpha.com. The titles are as follows: “Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American …” released on May 16, 2018, “Benzinga’s Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer’s Trial …” on May 10, 2018, “Adaptimmune Reports First Quarter 2018 Financial Results and Business Update” with a publish date: May 09, 2018, “Adaptimmune Therapeutics (ADAP) Data with NY-ESO and MAGE-A10 Study Update to be Presented at ASCO” and the last “Don’t Buy L Brands – Cramer’s Lightning Round (5/15/18)” with publication date: May 16, 2018.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.